GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached stat
If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York startup Metsera.
Welcome to, or welcome back to, the 5th Operationalize: Expanded Access Programs Summit 2025!
Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density that could undermine its ability to compete in t
BioNTech is clearly impressed with what it has seen with partner Biotheus' bispecific antibody for cancer, opting to buy the company outright to get full control of the drug.
Editor's Picks
